描述在1期临床试验中的儿科瘤患者
Andrea Cuviello1, Mariela Trejo2, Emily Zeng3
1Division of Palliative Medicine, Phoenix Children's, Phoenix, Arizona, USA.
Pediatric blood & cancer
|September 6, 2025
概括
在1期癌症试验中,儿童通常会接受息治疗 (PPC),但往往是晚期发生的. 早期的PPC整合可以改善这些脆弱患者的终身护理和规划.
科学领域:
- 儿童瘤学
- 临床试验
- 缓和护理
- 在生命末期的护理
背景情况:
- 小儿瘤的第一阶段试验可能会导致毒性以外的不良影响,包括延迟预先的护理计划和低于最佳的终生护理 (EoL).
- 儿童息治疗 (PPC) 可以支持这些患者的症状管理和EOL规划.
- 关于在1期癌症研究中整合PPC的数据有限.
研究的目的:
- 调查1期临床试验中的儿科瘤患者的儿科息护理咨询模式.
- 评估与第一阶段临床试验相关的PPC转诊时间.
- 突出需要在这个群体中更早地进行PPC整合.
主要方法:
- 在9年的临床试验中对儿科瘤患者的回顾性医疗记录.
- 数据收集包括社会人口统计,临床和EOL变量.
- 对收集的数据进行了描述性分析.
主要成果:
- 在539名患者中,82%的患者死亡. 中枢神经系统瘤是最常见的诊断 (44%).
- 大多数患者 (68%) 接受了PPC咨询,但只有21%的患者在参加第一阶段试验之前接受了咨询.
- 研究的中位时间为62天,随着随后的参与减少.
结论:
- 虽然大多数1期试验的儿科患者接受PPC,但转诊往往会延迟到试验注册后.
- 系统和早期整合PPC对于优化高危儿科瘤患者的EoL支持,护理和规划至关重要.
- 早期参与PPC可能会为面对晚期癌症的患者和家人带来最大的好处.
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
7.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
7.5K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K


